Metformin use and prostate cancer risk

Area of Science:

• Oncology
• Endocrinology
• Epidemiology

Background:

• Metformin, a common diabetes medication, may influence prostate cancer (PCa) development through mechanisms like reducing hyperinsulinemia or direct anti-cancer effects.
• Understanding the relationship between metformin and PCa risk is crucial for managing diabetes and cancer prevention strategies.

Purpose of the Study:

• To investigate the association between metformin usage and the diagnosis of prostate cancer.
• To compare the PCa risk in metformin users versus non-users, and users of other diabetes medications.

Main Methods:

• A nested case-control study was conducted in Denmark using data from the Danish Cancer Registry and prescription databases (1989-2011).
• 12,226 prostate cancer cases were identified and matched with 122,260 controls using risk-set sampling.
• Metformin exposure was determined by redeemed prescriptions, with logistic regression used to calculate odds ratios (ORs) and confidence intervals (CIs).

Main Results:

• Metformin users showed a significantly decreased risk of PCa diagnosis (adjusted OR: 0.84; 95% CI, 0.74-0.96) compared to never-users.
• No reduced risk of PCa was observed for diabetics on no medication or other oral hypoglycemics.
• Insulin users also showed a reduced risk (aOR: 0.77; 95% CI, 0.64-0.93).
• In a subgroup analysis of men with PSA testing, metformin use was strongly associated with decreased PCa risk (aOR: 0.66; 95% CI, 0.51-0.86).

Conclusions:

• Metformin use is associated with a lower risk of prostate cancer diagnosis.
• Unlike metformin, other oral hypoglycemic agents did not demonstrate a reduced risk for PCa.
• The findings suggest a potential protective role for metformin in prostate cancer development, particularly in diabetic patients.